RGNX is focused on developing, commercializing and licensing recombinant adeno-associated virus gene therapy with a proprietary delivery platform to treat rare diseases. RGNX is commercializing gene therapy products administered directly into the body, or in vivo, based on a NAV Technology Platform. Its NAV Technology Platform is currently being applied in the development of 23 product candidates for a variety of diseases, Regenxbio said, with exclusive rights to over 100 patents and patent applications worldwide.
November 5, 2015
RegMed’s close: as the sector balloon deflates, BLUE takes a BIG hit joined by JUNO, ONCE, QURE and KITE
November 4, 2015
RegMed’s close: retreating, reversing and reverting to maintain gains
November 3, 2015
RegMed’s close: piloting the portfolio, the pricing pattern is full
November 2, 2015
RegMed’s close: another wild swing, a short-term feeding frenzy?
October 29, 2015
RegMed’s close: strength sputters, who and what is rowing this “boat”?
October 27, 2015
RegMed’s close: the sector is caught in limbo stuck between markets, time to financial results, the FED and expectation
October 26, 2015
RegMed’s close: the need to recoup losses is greater than ever
October 26, 2015
RegMed’s mid-day: riding the bucking bronco
October 23, 2015
RegMed's close: the screen turned green as stocks retrace from oversold positions
October 22, 2015
RegMed’s close: another fear indicator, which CEO is fulfilling the role of managing your investment
35 companies, 1 interpreter!
Insight, foresight and recommendation
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2026 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.